Another milestone achieved – Bentley sold its 300,000th BeGraft

Another milestone achieved – Bentley sold its 300,000th BeGraft

LEIPZIG – 7^th June 2023, Bentley, a leading manufacturer of balloon expandable covered stents, announced at the annual LINC meeting in Leipzig, Germany, that it has reached an important milestone having sold the 300,000^th BeGraft. This milestone was celebrated appropriately at the Bentley booth at the Leipzig Interventional Course (LINC), which is taking place from 6 to 9 June 2023.

After launching the first BeGraft in 2012, the product found its way quickly to the clinics used in the most advanced and challenging endovascular procedures. The BeGraft is available in over 80 countries and became the market leader in most of them. With this steep growth Bentley is experiencing, the company proudly announced the sale of its 300,000^th BeGraft stent, which is a tremendous achievement.

Martijn Nugteren, Director Sales & Marketing at Bentley, is delighted with this six-figure number and mentioned in a statement “it is amazing what we have achieved with the BeGraft in such a short time, we were able to treat so many patients globally, giving them the best stent for the treatment of their vascular disease.” He also highlighted that “thanks to the acquisition of Qmedics in mid-April, Bentley is ready for the future growth of the BeGraft covered stent portfolio, which is much needed with the expected new indication and state of the art pipeline that we have.”

The 300,000^th BeGraft was sold to the company NovaHealth in Thailand, who is a proud partner of Bentley since 2015.

BePart of Bentley's exciting journey and upcoming milestones by following Bentley on LinkedIn. For product availability or further information, check www.bentley.global or send an email to info@bentley.global.

Contact: Matthias Bleesen, Communication & Event Coordinator, m.bleesen@bentley.global, +49 7471 984 995 631